Copyright
©2010 Baishideng Publishing Group Co.
World J Clin Oncol. Feb 10, 2011; 2(2): 80-93
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.80
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.80
Inhibitor | Tyrosine kinase target | Neoplasm(s) targeted | Clinical status |
Bcr-Abl inhibitors | |||
Imatinib mesylate (STI571) | Bcr-Abl, Kit, PDGFRβ | CML, ALL, GISTs | Approved |
Nilotinib (AMN107) | BcrAbl, Kit, PDGFRβ | CML, Pcp ALL, HS, SM | Approved |
Tyrphostin AG1024 | Bcr-Abl, P-Akt | CML (refract to STI571) | Preclinical |
ON012380 | Bcr-Abl | CML | Phase I |
Tyrphostin AG957 | Bcr-Abl | CML | Preclinical |
Adaphostin | Bcr-Abl | CML | Preclinical |
NS-187 | Bcr-Abl, Lyn | CML, Pcp ALL | Preclinical |
SRC family inhibitors | |||
Dasatinib (BMS354825) | Bcr-Abl, SRC | Adult CML, Pcp ALL | Approved |
SKI-606 | Bcr-Abl, SRC | Pcp leukemia, breast | Phase I/II |
AZD0530 | Bcr-Abl, SRC | Solid tumors | Phase I |
Lung, liver, colorectal | Phase II | ||
TG100435 | SRC, Lyn, abl, yes, lck, EphB4 | Anti-cancer | Preclinical |
PD166326 | Bcr-Abl, SRC, lyn | CML | Preclinical |
PD180970 | Bcr-Abl, SRC, Kit | CML | Preclinical |
AZM475271 | SRC | Pancreatic | Preclinical |
CGP76030 | Bcr-Abl, SRC | CML, prost, bone met | Preclinical |
PP1 | FYN, Lck, Kit, Bcr-Abl | CML | Preclinical |
PP2 | SRC, Lck, Fyn, Hck | Colon | Preclinical |
AP-23236 | SRC | Bone metastases | Preclinical |
PD173955 + 56 | BA, Kit, csk, PDGFRβ, EGFR | CML | Preclinical |
SU6656 | Scr, Fyn, Yes, Lyn | Lymphoma | Preclinical |
CGP77675 | SRC | Bone | Preclinical |
SU11333 + 36 | SRC | Breast, colon | Preclinical |
JAK inhibitors | |||
CP-690 550 | JAK3 | Immunogenic | Preclinical |
AG-490 | JAK2/3, EGFR | Leukemia, glioma | Preclinical |
WHI-P154 | JAK3, Hck, Syk | Neural precursor cells | Preclinical |
WHI-P131 | JAK3 | Leukemia, GVHD | Preclinical |
WP-1034 | JAK, Stat | AML | Preclinical |
LFM-A13 | JAK2, BTK | Leukemia | Preclinical |
- Citation: Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol 2011; 2(2): 80-93
- URL: https://www.wjgnet.com/2218-4333/full/v2/i2/80.htm
- DOI: https://dx.doi.org/10.5306/wjco.v2.i2.80